Skip to search formSkip to main contentSkip to account menu

alectinib

Known as: 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-, 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile 
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration… 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (3)

AF802Alecensaalectinib hydrochloride

Broader (1)

CH5424802
Kinase Inhibitors [MoA]NCIt Antineoplastic Agent TerminologyRO5424802Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.
9093Background: Alectinib was recently approved for first-line treatment of advanced ALK+ NSCLC based on the ALEX trial, which… 
2018
2018
Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population.
e21133Background: Phase III studies conducted in Japanese (J-ALEX; JapicCTI-132316) and global (ALEX; NCT02075840) patients with… 
2017
2017
What can we learn from 3 phase III trials of ASCEND-4: ceritinib vs . platinum/pemetrexed with pemetrexed maintenance, PROFILE 1004: crizotinib vs . platinum/pemetrexed, and J-ALEX: alectinib vs…
The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene is observed in 4–5% of non… 
Review
2017
Review
2017
The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC : Which ALK TKI to Use Upfront ?
Introduction The identification of the EML4-ALK fusion oncogene in 2007 as a driver of pathogenesis, in the 2% to 7% of patients… 
2016
2016
A case series of eight patients treated with alectinib including a case of interstitial lung disease
Alectinib is a second-generation inhibitor of anaplastic lymphoma kinase (ALK) and has been approvedfor the treatment of ALK… 
2016
2016
First-Line Alectinib Tops Crizotinib in ALK-Positive NSCLC
Alectinib yielded significantly prolonged progression-free survival compared with crizotinib in ALK-positive NSCLC patients… 
2016
2016
Transformation to small cell lung cancer following treatment with an ALK inhibitor
2015
2015
Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Touch MEdical MEdia Abstract The development of oncogene-directed targeted therapies represents a new paradigm in the treatment… 
2015
2015
Alectinib Shows Response in Crizotinib-Refractory NSCLC
The ALK inhibitor alectinib was highly active and well-tolerated in patients with ALK-rearranged, crizotinib-refractory, advanced… 
2015
2015
NEW DRUG APPROVALS Alectinib for NSCLC
  • 2015
  • Corpus ID: 8377023
NEW DRUG APPROVALS Alectinib for NSCLC The FDA has approved alectinib (Alecensa, Genentech) to treat patients with advanced…